Section Arrow
ATHA.NASDAQ
- Athira Pharma Inc.
Quotes are at least 15-min delayed:2025/12/21 15:09 EST
Regular Hours
Last
 6.97
+0.25 (+3.72%)
Day High 
7.25 
Prev. Close
6.72 
1-M High
8.36 
Volume 
1.40M 
Bid
6.92
Ask
6.98
Day Low
6.37 
Open
6.71 
1-M Low
3.8001 
Market Cap 
26.50M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.22 
20-SMA 4.27 
50-SMA 4.2 
52-W High 8.36 
52-W Low 2.19549 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.67/--
Enterprise Value
27.31M
Balance Sheet
Book Value Per Share
6.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.18+3.29+30.21%-- 
RXRXRecursion Pharmaceuticals4.26-0.18-4.05%-- 
IBRXImmunityBio2.08-0.01-0.48%-- 
PBMPsyence Biomedical Ltd1-0.46-31.51%0.04PE
GOVXGeoVax Labs0.1592-0.0809-33.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.